Immunomodulatory proteins are proteins capable of modifying or regulating one or more immune functions. Immune checkpoints, including inhibitory receptors and ligands, are one type of immunomodulators.
Compugen has extended its predictive discovery capabilities for cancer immunotherapy beyond the successful initial focus on immune checkpoints, and through the application of additional predictive platforms has discovered novel immunomodulatory protein candidates.
Proteins evolve to maintain their function in an ever-changing environment. Different proteins might have a different evolutionary rate and pattern depending on their environment.
Proteins that participate in immune responses to intruding pathogens are subject to an evolutionary pressure that is different from non-immune related proteins. We have devised a model to detect immune proteins based on their enhanced evolutionary rates. The predictive algorithm was incorporated into Compugen’s discovery infrastructure and integrated with existing tools to discover novel immune target candidates for cancer immunotherapy.
Macrophages are immune cells that engulf and digest dying or dead cells, cellular debris and pathogens. As such, they have a critical role in initiating and regulating immune defense mechanisms.
In cancer, tumor associated macrophages (TAMs) are found within the tumor microenvironment and have an important role in promoting progression and invasion of tumor cells, and in suppression of anti-cancer immunity. Therefore, the neutralization of TAMs has become an attractive approach for cancer immunotherapy. Various pharmaceutical and biotechnology companies have begun to develop therapies targeting TAMs, and clinical trials are at early stages.
In cancer, tumor associated macrophages (TAMs) are found within the tumor microenvironment and have an important role in promoting or suppressing anti-cancer immunity. Therefore, the neutralization of immuno-suppressive TAMs has become an attractive approach for cancer immunotherapy. Our prediction of novel TAM targets relies on a specialized algorithm that employs the Company’s MED and LINKS Platform. Several potential TAM targets were predicted, and initial positive validation results have been disclosed for one target protein.
Myeloid biology is a critical component of immune suppression. The myeloid lineage of the immune system includes macrophages, immune cells that are highly immune suppressive in the tumor microenvironment, and that can affect the anti-tumor immune response via multiple mechanisms of action. With the aim of complementing and expanding the patient population responsive to checkpoints inhibitors, blocking myeloid targets may serve as the next wave of cancer immunotherapies. The Company’s LINKS Platform was enhanced to discover new myeloid targets within the tumor microenvironment. Myeloid CGEN-target candidates have been identified within the tumor microenvironment of multiple cancers and are pursued by the Company.